Industry NewsEisai's Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China
Industry NewsNovel Drug for Mild-to-Moderate Alzheimer's Disease Demonstrates Safety and Tolerability at 18-Months
Industry NewsAnticancer Agent Lenvatinib Designated for Priority Review and Approval by CFDA for Hepatocellular Carcinoma
Industry NewsEisai to Present Latest Data on Perampanel and Rufinamide at 71st American Epilepsy Society Annual Meeting
